Study S001888

A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02146079
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 44
Start: 2014-05-21
Primary completion: 2014-10-20
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2; Healthy
Interventions: DRUG:semaglutide; DRUG:placebo
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1147-6660; REGISTRY:JapicCTI-142550

Registered primary outcomes

Area under the plasma semaglutide concentration-time curve [During a dosing interval (0-168 hours) at steady state]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020993	A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects. Ikushima I, Advances in therapy	2018	Randomized trial	PMID 29536338 DOI	cites ClinicalTrials.gov:NCT02146079; cites JapicCTI:JAPICCTI-142550; registry reference RESULT:29536338